The bill amends the Federal Food, Drug, and Cosmetic Act to set up a formal process for externally led, science‑focused drug development meetings (EL–SFDD) convened by the Reagan‑Udall Foundation to address scientific challenges in developing therapies for rare diseases and conditions.
These meetings are meant to produce technical alignment—on trial designs, endpoints, biomarkers, natural‑history controls, and manufacturing standards—while creating a public record of the discussion. The measure directs FDA participation, requires public reporting about how meeting input was used in regulatory risk‑benefit work, and authorizes modest appropriations to support the program.
At a Glance
What It Does
The bill requires the Secretary of HHS to contract with the Reagan‑Udall Foundation to convene externally led, science‑focused drug development meetings addressing rare diseases. It mandates a permanent multistakeholder steering committee, minimum annual meeting frequency, publicly available transcripts and summaries, and agency reporting on how meeting input informed approvals.
Who It Affects
Directly affected parties include sponsors developing drugs for rare diseases (small biotech and larger firms), FDA review divisions (CDER, CBER, CDRH), the Reagan‑Udall Foundation (as convener), academic clinicians and researchers, and patient organizations that participate in topic selection and meetings.
Why It Matters
This creates a formal mechanism for multistakeholder scientific alignment outside of traditional FDA pre‑submission meetings and advisory committees. That can accelerate development paths and reduce uncertainty about endpoints and trial design, but it also embeds non‑governmental actors more deeply into the regulatory ecosystem and generates new transparency and resource obligations for FDA and the Foundation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Scientific EXPERT Act directs HHS to use the Reagan‑Udall Foundation as a qualified third‑party convenor to run externally led, science‑focused drug development (EL–SFDD) meetings targeted at rare diseases. The Foundation must organize meetings that bring together academic experts, clinicians, drug sponsors, scientific societies, patient groups, and appropriate FDA review staff to tackle technical questions—such as what clinical endpoints or biomarkers are acceptable, how natural‑history data can be used as controls, or what manufacturing standards should apply for a specific therapeutic approach.
To choose topics and participants, the Foundation will maintain a permanent multistakeholder steering committee that reviews suggested topics, applies explicit selection criteria (like unmet need, population size, and potential for broader applicability), and recommends meeting priorities. The planning process requires consultation with FDA staff, industry, patient organizations, and clinical experts so that each meeting has targeted objectives, a proposed agenda, and a defined invitee list.After each meeting the Foundation must publish a transcript, a recording, and a consensus‑focused summary analysis within a statutory timeframe; those outputs must identify areas of agreement, where more data or clarification is needed, and any next steps agreed with FDA.
The statute also requires FDA to disclose, when it approves or licenses a drug, whether an EL–SFDD meeting was relevant to that decision and to describe how the meeting input was incorporated into the agency’s risk‑benefit assessment. Finally, the law authorizes limited appropriations for the program and allows the Foundation to accept outside funds to plan and run meetings.
The Five Things You Need to Know
The Foundation must convene at least four EL–SFDD meetings per year, each focused on a different rare disease or group of rare diseases.
A permanent Science‑Focused Drug Development Multistakeholder Steering Committee will include representatives from CDER, CBER, and CDRH plus academics, licensed clinicians, patient representatives, and industry and will operate under the Foundation’s conflict‑of‑interest rules.
The Foundation must post a transcript and recording of each EL–SFDD meeting and a summary analysis identifying consensus points, outstanding questions, and agreed next steps within 180 days of the meeting.
When FDA approves or licenses a drug, the agency must state whether an EL–SFDD meeting was relevant to the decision and describe how it incorporated input from that meeting into its risk‑benefit assessment.
Congress authorized $1,000,000 per fiscal year for 2025–2029 to carry out the statute’s requirements, and the Foundation may solicit or accept additional funds to support meetings.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statutory authorization for Foundation‑led science meetings
This subsection creates the statutory hook: HHS must develop and implement a process under which the Reagan‑Udall Foundation convenes externally led, science‑focused meetings. The provision frames the purpose—discussing scientific obstacles and aligning on approaches such as trial designs or surrogate endpoints—rather than creating formal advisory opinions. Practically, it authorizes the Secretary to delegate convening and operational tasks to a trusted third party while retaining oversight responsibilities.
Arrangement with the Foundation, minimum meetings, and steering committee
The bill requires an explicit arrangement with the Reagan‑Udall Foundation and sets a minimum floor of four meetings annually. It also requires the Foundation to establish a permanent multistakeholder steering committee to vet and prioritize topics. The steering committee’s membership must include FDA center representatives and a cross‑section of external stakeholders; members are bound by Foundation conflict‑of‑interest policies. This structure centralizes topic selection and creates a standing body to guard consistency and apply the bill’s selection criteria.
Meeting planning and stakeholder consultation
Before each EL‑SFDD meeting the Foundation must develop targeted objectives, an agenda, and an invitee list through consultation with FDA staff, industry sponsors, patient groups, and clinical experts. That planning duty is designed to produce narrowly scoped, technically actionable meetings rather than broad public forums. The statutory requirement for this multi‑party planning creates expectations about inclusivity and technical preparedness that will drive resource needs on both the Foundation and FDA sides.
Post‑meeting public materials and analytical summaries
Within 180 days of a meeting the Foundation must post a transcript, recording, and a summary analysis that identifies consensus areas, outstanding questions, and next steps agreed with FDA. Those public materials create a transparent record of technical conversations that sponsors, clinicians, patients, and other regulators can use—but they also require the Foundation to manage redaction and confidentiality where trade secrets or exempt information are involved.
FDA participation, limits, definitions, and funding
The statute requires appropriate FDA review division representatives to participate in each meeting and defines key terms (including use of the rare disease definition in section 526). It also states several rules of construction—most notably that these meetings do not create entitlement to consultation, do not change protections for confidential commercial information, and do not increase review cycles. Finally, it authorizes $1,000,000 annually for FY2025–2029 for implementation and allows the Foundation to solicit additional funds.
Follow‑on agency actions: incorporation statements and annual reporting
Section 770B requires FDA to disclose in approval or licensure actions whether an EL‑SFDD meeting was relevant and to describe how the agency incorporated meeting input into its risk‑benefit assessment. It also mandates an annual report to Congress summarizing meeting topics and numbers, FDA participation, program impact on agency workload, and an assessment of how meeting input was used across the drug development lifecycle. Those obligations create audit points and formalize expectations for traceability between external scientific discussions and regulatory decisions.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Rare disease patients and patient organizations — gain structured forums to influence endpoint selection, trial designs, and manufacturing considerations that can shorten development timelines and increase the chance a therapy reaches approval.
- Academic clinicians and disease experts — receive a formal channel to surface natural history data, biomarker strategies, and trial designs to regulators and sponsors without relying solely on ad hoc meetings.
- Small and mid‑sized sponsors developing rare‑disease therapies — get earlier alignment on acceptable trial designs and surrogate endpoints that can lower technical and regulatory uncertainty and potentially reduce development cost and time.
- FDA review divisions — obtain consolidated, documented technical input from diverse external experts in a single forum, which can improve scientific context for difficult benefit‑risk judgments and provide a traceable record for regulatory reasoning.
- Reagan‑Udall Foundation — expands its convening role, visibility, and potential revenue streams through statutory authorization and permissive fundraising language.
Who Bears the Cost
- Food and Drug Administration — must dedicate review staff to participate in meetings, respond to follow‑up actions, and produce the required agency disclosures and annual report, all of which consume review resources.
- Reagan‑Udall Foundation — assumes operational responsibility for convening, producing public materials, and managing conflicts of interest and confidentiality, requiring sustained staffing and governance investments.
- Sponsors and industry participants — will allocate scientific and legal resources to prepare for meetings, protect proprietary data, and potentially respond to public summaries that could affect competitive positioning.
- Patient organizations and smaller stakeholder groups — may need to devote limited resources to participate meaningfully in planning and meetings if they want their perspectives represented.
- Congress and oversight entities — bear indirect costs of monitoring implementation and evaluating the program’s impact on regulatory outcomes.
Key Issues
The Core Tension
The central dilemma is whether embedding structured, externally led scientific conversations into the regulatory ecosystem will speed development through better technical alignment, or whether it will dilute regulatory independence and introduce conflicts—especially when private sponsors and well‑resourced advocates shape agendas and public records that the agency must later explain in approvals. The bill seeks to balance collaboration and transparency with confidentiality and impartiality, but implementation choices (conflict policies, redaction standards, depth of FDA disclosures, and funding sources) will determine which side of that balance dominates.
The bill advances transparency and early scientific alignment, but it leaves several implementation questions unresolved. It delegates heavy operational duties and conflict‑management to the Foundation while requiring FDA participation and post‑approval disclosures; how the Foundation’s COI rules will interact with FDA ethics standards and advisory committee practices is unclear.
The statute protects trade secrets in principle, yet mandates posting recordings and transcripts with a short publication window—redaction procedures and standards for withholding exempt material will drive legal and operational complexity.
The requirement that FDA describe how meeting input was incorporated into risk‑benefit assessments creates an accountability mechanism, but it does not define the depth or format of that disclosure. That invites variability in practice: a single sentence saying a meeting was “considered” would meet the text but carry little informational value.
The authorization of modest annual appropriations plus permissive fundraising may fund initial activity but raises sustainability questions: will the program rely on external funds that could skew participation toward better‑resourced sponsors or organizations? Finally, selection criteria for meetings privilege diseases where alignment could have “broader impact,” which is sensible but risks favoring diseases with already active development pipelines over truly neglected conditions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.